Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors

Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2020-10, Vol.56 (4), p.2000279
Hauptverfasser: Weatherald, Jason, Bondeelle, Louise, Chaumais, Marie-Camille, Guignabert, Christophe, Savale, Laurent, Jaïs, Xavier, Sitbon, Olivier, Rousselot, Philippe, Humbert, Marc, Bergeron, Anne, Montani, David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 2000279
container_title The European respiratory journal
container_volume 56
creator Weatherald, Jason
Bondeelle, Louise
Chaumais, Marie-Camille
Guignabert, Christophe
Savale, Laurent
Jaïs, Xavier
Sitbon, Olivier
Rousselot, Philippe
Humbert, Marc
Bergeron, Anne
Montani, David
description Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.
doi_str_mv 10.1183/13993003.00279-2020
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04526808v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2412995434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ec048a5ea781b84d645aadfddfd83ca481bb50d56ecd5f19c8f228059569f93e3</originalsourceid><addsrcrecordid>eNo9kEtLxDAUhYMozjj6CwTpUhcdb15tsnAxDuoIBV3oOqRpykTbZmxaYf69rfOACxcO59zHh9A1hjnGgt5jKiUFoHMAksqYAIETNB3VeJRP0RQk0BhLmkzQRQhfADhhFJ-jCSWcpCmDKXp476vaN7rdRsbXm8oZ3TnfhMiX0aNp40VeRd229cE1Nvp2jQ42cs3a5a7zbbhEZ6Wugr3a9xn6fH76WK7i7O3ldbnIYkMF62JrgAnNrU4FzgUrEsa1LspiKEGNZoOacyh4Yk3BSyyNKAkRwCVPZCmppTN0t5u71pXatK4e7lVeO7VaZGrUgHGSCBC_ePDe7ryb1v_0NnSqdsHYqtKN9X1QhGEiJWeUDVa6s5rhwdDa8jgbgxoZqwNj9c9YjYyH1M1-QZ_XtjhmDlDpHxZPdgs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2412995434</pqid></control><display><type>article</type><title>Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Weatherald, Jason ; Bondeelle, Louise ; Chaumais, Marie-Camille ; Guignabert, Christophe ; Savale, Laurent ; Jaïs, Xavier ; Sitbon, Olivier ; Rousselot, Philippe ; Humbert, Marc ; Bergeron, Anne ; Montani, David</creator><creatorcontrib>Weatherald, Jason ; Bondeelle, Louise ; Chaumais, Marie-Camille ; Guignabert, Christophe ; Savale, Laurent ; Jaïs, Xavier ; Sitbon, Olivier ; Rousselot, Philippe ; Humbert, Marc ; Bergeron, Anne ; Montani, David</creatorcontrib><description>Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00279-2020</identifier><identifier>PMID: 32527740</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><subject>Life Sciences</subject><ispartof>The European respiratory journal, 2020-10, Vol.56 (4), p.2000279</ispartof><rights>Copyright ©ERS 2020.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ec048a5ea781b84d645aadfddfd83ca481bb50d56ecd5f19c8f228059569f93e3</citedby><cites>FETCH-LOGICAL-c384t-ec048a5ea781b84d645aadfddfd83ca481bb50d56ecd5f19c8f228059569f93e3</cites><orcidid>0000-0002-6862-8975 ; 0000-0002-8545-4452 ; 0000-0003-0703-2892 ; 0000-0002-1942-1951 ; 0000-0002-9358-6922 ; 0000-0002-0615-4575</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32527740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04526808$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Weatherald, Jason</creatorcontrib><creatorcontrib>Bondeelle, Louise</creatorcontrib><creatorcontrib>Chaumais, Marie-Camille</creatorcontrib><creatorcontrib>Guignabert, Christophe</creatorcontrib><creatorcontrib>Savale, Laurent</creatorcontrib><creatorcontrib>Jaïs, Xavier</creatorcontrib><creatorcontrib>Sitbon, Olivier</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Humbert, Marc</creatorcontrib><creatorcontrib>Bergeron, Anne</creatorcontrib><creatorcontrib>Montani, David</creatorcontrib><title>Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.</description><subject>Life Sciences</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLxDAUhYMozjj6CwTpUhcdb15tsnAxDuoIBV3oOqRpykTbZmxaYf69rfOACxcO59zHh9A1hjnGgt5jKiUFoHMAksqYAIETNB3VeJRP0RQk0BhLmkzQRQhfADhhFJ-jCSWcpCmDKXp476vaN7rdRsbXm8oZ3TnfhMiX0aNp40VeRd229cE1Nvp2jQ42cs3a5a7zbbhEZ6Wugr3a9xn6fH76WK7i7O3ldbnIYkMF62JrgAnNrU4FzgUrEsa1LspiKEGNZoOacyh4Yk3BSyyNKAkRwCVPZCmppTN0t5u71pXatK4e7lVeO7VaZGrUgHGSCBC_ePDe7ryb1v_0NnSqdsHYqtKN9X1QhGEiJWeUDVa6s5rhwdDa8jgbgxoZqwNj9c9YjYyH1M1-QZ_XtjhmDlDpHxZPdgs</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Weatherald, Jason</creator><creator>Bondeelle, Louise</creator><creator>Chaumais, Marie-Camille</creator><creator>Guignabert, Christophe</creator><creator>Savale, Laurent</creator><creator>Jaïs, Xavier</creator><creator>Sitbon, Olivier</creator><creator>Rousselot, Philippe</creator><creator>Humbert, Marc</creator><creator>Bergeron, Anne</creator><creator>Montani, David</creator><general>European Respiratory Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-6862-8975</orcidid><orcidid>https://orcid.org/0000-0002-8545-4452</orcidid><orcidid>https://orcid.org/0000-0003-0703-2892</orcidid><orcidid>https://orcid.org/0000-0002-1942-1951</orcidid><orcidid>https://orcid.org/0000-0002-9358-6922</orcidid><orcidid>https://orcid.org/0000-0002-0615-4575</orcidid></search><sort><creationdate>20201001</creationdate><title>Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors</title><author>Weatherald, Jason ; Bondeelle, Louise ; Chaumais, Marie-Camille ; Guignabert, Christophe ; Savale, Laurent ; Jaïs, Xavier ; Sitbon, Olivier ; Rousselot, Philippe ; Humbert, Marc ; Bergeron, Anne ; Montani, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ec048a5ea781b84d645aadfddfd83ca481bb50d56ecd5f19c8f228059569f93e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weatherald, Jason</creatorcontrib><creatorcontrib>Bondeelle, Louise</creatorcontrib><creatorcontrib>Chaumais, Marie-Camille</creatorcontrib><creatorcontrib>Guignabert, Christophe</creatorcontrib><creatorcontrib>Savale, Laurent</creatorcontrib><creatorcontrib>Jaïs, Xavier</creatorcontrib><creatorcontrib>Sitbon, Olivier</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Humbert, Marc</creatorcontrib><creatorcontrib>Bergeron, Anne</creatorcontrib><creatorcontrib>Montani, David</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weatherald, Jason</au><au>Bondeelle, Louise</au><au>Chaumais, Marie-Camille</au><au>Guignabert, Christophe</au><au>Savale, Laurent</au><au>Jaïs, Xavier</au><au>Sitbon, Olivier</au><au>Rousselot, Philippe</au><au>Humbert, Marc</au><au>Bergeron, Anne</au><au>Montani, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>56</volume><issue>4</issue><spage>2000279</spage><pages>2000279-</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>32527740</pmid><doi>10.1183/13993003.00279-2020</doi><orcidid>https://orcid.org/0000-0002-6862-8975</orcidid><orcidid>https://orcid.org/0000-0002-8545-4452</orcidid><orcidid>https://orcid.org/0000-0003-0703-2892</orcidid><orcidid>https://orcid.org/0000-0002-1942-1951</orcidid><orcidid>https://orcid.org/0000-0002-9358-6922</orcidid><orcidid>https://orcid.org/0000-0002-0615-4575</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2020-10, Vol.56 (4), p.2000279
issn 0903-1936
1399-3003
language eng
recordid cdi_hal_primary_oai_HAL_hal_04526808v1
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Life Sciences
title Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T16%3A37%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulmonary%20complications%20of%20Bcr-Abl%20tyrosine%20kinase%20inhibitors&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Weatherald,%20Jason&rft.date=2020-10-01&rft.volume=56&rft.issue=4&rft.spage=2000279&rft.pages=2000279-&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00279-2020&rft_dat=%3Cproquest_hal_p%3E2412995434%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2412995434&rft_id=info:pmid/32527740&rfr_iscdi=true